Table 2.
Parameters | DED patients in SLE (n = 33) | Non- DED patients in SLE (n = 63) | P |
---|---|---|---|
Alcohol use, n(%) | 2 (6.1%) | 2 (3.2%) | 0.893 |
Tobacco use, n(%) | 1 (3.0%) | 2 (3.2%) | 0.969 |
Corticosteriods use, n(%) | 24 (72.7%) | 43 (68.3%) | 0.650 |
Hydroxychloroquine use, n(%) | 20 (60.6%) | 33 (52.4%) | 0.441 |
Hypertension | 3 (9.1%) | 4 (6.3%) | 0.624 |
Diabetes | 3 (9.1%) | 3 (4.8%) | 0.698 |
CRP, mg/L | 0.70 (0.20,1.35) | 0.60 (0.20,2.10) | 0.978 |
C3,g/L | 0.86 (0.68,1.02) | 0.78 (0.64,0.92) | 0.151 |
ESR, mm/h | 19.0 (13.5,34.5) | 20.0 (11.0,33.0) | 0.746 |
SLEDAI | 7.0 (5.0,13.5) | 4.0 (2.0,8.5) | <0.05 |
Age | 42.1 ± 11.2 | 33.2 ± 10.5 | <0.05 |
Data is presented as mean ± SD, median and interquartile range (IQR, 25–75%), or number of participants (% of participants). SLE, Systemic Lupus Erythematosus; CRP, C-Reactive Protein; C3, complement levels; ESR, Erythrocyte Sedimentation Rate; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index. The bold values means significant results.